Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 18 May 2017

Annual Report 2016 Active Biotech AB (publ)

Active Biotech    

Published: 14:30 CEST 18-05-2017 /GlobeNewswire /Source: Active Biotech / : ACTI /ISIN: SE0001137985

Annual Report 2016 Active Biotech AB (publ)

 

Active Biotech's Annual Report 2016 is now available för download at www.activebiotech.com.

The Annual Report will only be digitally distributed. The English version will be available within short.

 

Lund, May 18, 2017

 

Tomas Leanderson

President & CEO

 

For further information, please contact:

Hans Kolam, CFO

Tel. +46 (0)46 192044

 

About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Anyara, cancer immunotherapy, previously in clinical Phase 1-2/3 development in patients with pancreatic-, lung- or renal cancer. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.

 

Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00

This information is information that Active Biotech AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 14.30 am CET on May 18, 2017.



Annual Report 2016 Active Biotech AB (publ)



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Active Biotech, Scheelevägen 22
Box 724, LUND 220 07,
If you would like to unsubscribe and stop receiving these e-mails click here.